Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.59 |
| ▸ | MAPK13 | O15264 | 8/20 | 0.59 |
| ▸ | MAPK12 | P53778 | 8/20 | 0.59 |
| ▸ | MAPK11 | Q15759 | 8/20 | 0.59 |
| ▸ | RAF1 | P04049 | 4/20 | 0.59 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.59 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.59 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.59 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.59 |
| ▸ | PRKCA | P17252 | 2/20 | 0.59 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.59 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4583748 | 1.00 | MAPK14 (0.59) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL4586046 | 1.00 | MAPK14 (0.59) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL8113515 | 0.95 | CSNK1D (0.56) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL8108392 | 0.91 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL8108276 | 0.91 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL8099919 | 0.90 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL8108398 | 0.90 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL4586184 | 0.89 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL4585684 | 0.89 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL8099788 | 0.87 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024150014-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERAPY-ASSOCIATED CYTOKINE RELEASE SYNDROME | Poolbeg Pharma (UK) Limited (GB) | 2024-07-18 | — | — | WO | disclosed |
| EP-4172314-A1 | CULTURE OF ORGANOIDS | Genome Research Limited (GB) | 2023-05-03 | — | — | EP | disclosed |
| WO-2021260195-A1 | CULTURE OF ORGANOIDS | GENOME RESEARCH LIMITED (GB) | 2021-12-30 | — | — | WO | disclosed |
| WO-2013086002-A1 | COMPOSITIONS, PROCESS OF PREPARATION OF SAID COMPOSITIONS AND METHOD OF TREATING CANCER | CELLWORKS RESEARCH INDIA PRIVATE LIMITED (IN) | 2013-06-13 | — | — | WO | disclosed |
| EP-1539121-A4 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1885181-A2 | INHIBITION OF P38 MARK FOR TREATMENT OF OBESITY | Smithkline Beecham Corporation (US) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006127678-A2 | INHIBITION OF P38 MARK FOR TREATMENT OF OBESITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-30 | — | — | WO | disclosed |
| EP-1337255-A4 | USE OF P38 INHIBITORS FOR THE TREATMENT OF INFLAMMATION-ENHANCED COUGH | SMITHKLINE BEECHAM CORP (US) | 2006-01-25 | — | — | EP | disclosed |
| EP-1539121-A2 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC. (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1223924-A4 | USE OF CSAIDS IN RHINOVIRUS INFECTION | SMITHKLINE BEECHAM CORP (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2004024083-A2 | METHODS OF BONE HEALING | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004019873-A2 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC. (US) | 2004-03-11 | — | — | WO | disclosed |
| EP-1337255-A2 | USE OF P38 INHIBITORS FOR THE TREATMENT OF INFLAMMATION-ENHANCED COUGH | SmithKline Beecham Corporation (US) | 2003-08-27 | — | — | EP | disclosed |
| EP-1337250-A2 | USE OF P38 INHIBITORS FOR THE TREATMENT OF SMOKE INHALATION | SmithKline Beecham Corporation (US) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002060869-A2 | USE OF P38 INHIBITORS FOR THE TREATMENT OF INFLAMMATION-ENHANCED COUGH | SMITHKLINE BEECHAM CORPORATION (US) | 2002-08-08 | — | — | WO | disclosed |
| EP-1223924-A2 | USE OF CSAIDS IN RHINOVIRUS INFECTION | SmithKline Beecham Corporation (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2002032862-A2 | USE OF P38 INHIBITORS FOR THE TREATMENT OF SMOKE INHALATION | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-25 | — | — | WO | disclosed |
| WO-2001019322-A2 | USE OF CSAIDS IN RHINOVIRUS INFECTION | SMITHKLINE BEECHAM CORPORATION (US) | 2001-03-22 | — | — | WO | disclosed |